X
<

How Celgene Is Positioned after 2Q17

PART:
1 2 3 4 5 6 7 8
Part 4
How Celgene Is Positioned after 2Q17 PART 4 OF 8

How Celgene’s Pomalyst Is Positioned after 2Q17

Pomalyst revenue trends

In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~7% growth quarter-over-quarter.

In the US, Pomalyst witnessed ~30% growth YoY and 12% growth quarter-over-quarter in 2Q17. Outside the US market, the drug witnessed ~13% growth on a YoY basis and ~1% growth quarter-over-quarter. Pomalyst’s growth in the multiple myeloma market share and an increase in treatment duration contributed to its US revenue growth. Pomalyst is the leading drug in the third-line share in the US and the European Union.

How Celgene’s Pomalyst Is Positioned after 2Q17

Interested in CELG? Don't miss the next report.

Receive e-mail alerts for new research on CELG

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The chart above represents the revenue trajectory of Pomalyst from 2Q16 to 2Q17. To learn more about Pomalyst, please read Why Pomalyst Could See Significant Revenue Growth in 2017.

Recent regulatory approval for combination therapy

In June 2017, the FDA approved Darzalex (daratumumab) in combination with Pomalyst and dexamethasone for the treatment of individuals with multiple myeloma who have undergone at least two previous therapies. The regulatory approval of the combination therapy could create a demand for Pomalyst in the United States.

Ongoing trial

Celgene (CELG) is conducting the Phase 3 OPTIMISMM trial with Pomalyst in combination with bortezomib and dexamethasone. This trial is evaluating the safety and efficacy in the treatment of relapsed/refractory multiple myeloma (or RRMM) compared to only bortezomib and dexamethasone therapy. Celgene anticipates data from the OPTIMISMM trial by the end of 2018.

Celgene’s Pomalyst faces competition from Johnson & Johnson’s (JNJ) Darzalex, Bristol-Myers Squibb’s (BMY) Empliciti, and Takeda Pharmaceuticals’ (TKPYY) Velcade.

The growth in sales of Celgene’s Pomalyst may strengthen the share price of the PowerShares QQQ ETF (QQQ). Celgene comprises ~1.6% of QQQ’s total portfolio holdings.

X

Please select a profession that best describes you: